GlobeNewswire Inc | Aug 31, 2021 07:00AM EDT

August 31, 2021

SALT LAKE CITY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that the Company will present at the following investor conferences in September:

Citis 16th Annual BioPharma Virtual ConferenceDate: September 8-10, 2021Format: 1x1 meetings

H.C. Wainwright 23rd Annual Global Investment Conference Date: September 13, 2021Time: 7:00 a.m. ETFormat: Corporate Presentation (pre-recorded), and 1x1 meetings

Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: September 21, 2021Time: 2:05 p.m. ETFormat: Corporate Presentation (live), and 1x1 meetings

2021 Cantor Virtual Global Healthcare ConferenceDate: September 27, 2021Time: 2:00 p.m. ETFormat: Corporate Presentation (live), and 1x1 meetings

Webcasts of the presentations will be available on the Events and Presentations section of the Clene website.

About Clene

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, is leading the way by using nanotechnology to treat energetic failure, which underlies many neurological diseases. Clene has innovated a novel nanotherapeutic platform to create a new class of drugs. Clenes lead drug candidate, CNM-Au8, is an aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases cellular energy production to accelerate neurorepair and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis (ALS), a Phase 2 trial examining disease progression via a novel electromyography technique in patients with early ALS, a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS), and Phase 2 brain target engagement studies in patients with Parkinsons disease (PD) and MS. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

CNM-Au8, a gold nanocrystal suspension, is a federally registered trademark of Clene Nanomedicine, Inc.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Clene's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clenes control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clenes ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clenes ability to achieve commercial success for its marketed products and drug candidates, if approved; Clenes ability to obtain and maintain protection of intellectual property for its technology and drugs; Clenes reliance on third parties to conduct drug development, manufacturing and other services; Clenes limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clenes clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in Clenes Annual Report filed on Form 10K, as well as discussions of potential risks, uncertainties, and other important factors in Clenes subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactGwendolyn SchankerLifeSci Communications(269) 921-3607gschanker@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

Source: Clene Inc.